Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination topical drug** containing **bacitracin**, **neomycin**, and **polymyxin B**—all antibiotics—with the addition of **lidocaine**, a local anesthetic[5][7][8]. It is used to **prevent and treat bacterial skin infections** associated with minor wounds, cuts, scrapes, and burns, while providing **pain relief** via the anesthetic effect of lidocaine[5][7][9]. - **Bacitracin** inhibits bacterial cell wall synthesis by interfering with dephosphorylation of lipid carrier molecules[5][7]. - **Neomycin** is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit[5][7]. - **Polymyxin B** disrupts bacterial cell membranes by interacting with phospholipids[5][7]. - **Lidocaine** blocks sodium channels, preventing nerve impulse transmission and producing localized numbness[5][7][8]. This combination offers broad-spectrum antibacterial coverage (Gram-positive and Gram-negative bacteria) and is applied topically in ointment form; it is available over-the-counter in various regions[5][7][8][9]. Primary indications are prevention and treatment of skin infection and pain relief in minor injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin + lidocaine + neomycin + polymyxin b.